Every week, I take a look at a few companies that lapped their profit targets. Leaving Wall Street's pros with quizzical looks on their faces can be a good thing. It usually means that the companies have more in the tank than analysts figured, and capital appreciation often follows.

Let's take a look at a few companies that humbled the prognosticators this past week.

Pfizer (NYSE:PFE) checked in with a cleaner bill of health than the market had been expecting. It earned an adjusted $0.68 a share for its latest quarter before a series of one-time items. Analysts figured that Pfizer would only be good for $0.59 per share. Sure, the drugmaker has its problems. It has had setbacks, and it has three years to reinvent itself before its top-selling drug loses patent protection and gets marked down by the presence of generic Lipitor knockoffs. Thumping expectations doesn't exactly prime the pipeline, but it's a good place to be if you're Pfizer.

Google (NASDAQ:GOOG) was another topper. The world's largest creator of online advertising revenue earned $3.18 a share during the first quarter, but it was actually $3.68 per share on an adjusted basis. It was under the latter of the two scenarios in which the pros were expecting the paid search giant to earn just $3.30 a share.

Google has been a beast on that front. It has clocked in ahead of profit targets in all but one quarter since going public nearly three years ago. It was a welcome report, especially since rival Yahoo! (NASDAQ:YHOO) had come up short two days earlier.

Then we have eBay (NASDAQ:EBAY) earning the "buy it now" honors. The Internet marketplace saw adjusted profits soar 39% higher to hit $0.33 a share. That was comfortably ahead of the $0.30 per share in profitability that was expected. The company also boosted its earnings guidance for all of 2007.

So, keep watching the companies that lap expectations. Over time, it will be a rewarding experience for investors as the market rewards the overachievers. That's the kind of surprise we look for in the Rule Breakers newsletter service. Want in? Check out a 30-day trial subscription.

Either way, come back next Monday to learn about more stocks that blew the market away.

Yahoo! and eBay have been Motley Fool Stock Advisor newsletter selections over the years. Pfizer is an Inside Value recommendation. Check into either newsletter for the next 30 days with a free trial subscription offer.

Longtime Fool contributor Rick Munarriz is a fan of toppers. He does not own shares in any of the companies in this story. He is also part of the Rule Breakers newsletter research team, seeking out tomorrow's ultimate growth stocks a day early. The Fool has a disclosure policy.